Ablynx N.v.

Galapagos Nv

Pascal Gerard Merchiers

Catelijne Stortelers

Peter Vanlandschoot

Francis Descamps

Regorius Leurs

Philippe Van Rompaey

Martine Smit

Maria Gonzalez Pajuelo

David Andre Baptiste Maussang-Detaille

Maarten Van Roy

Koenraad Frederik Florentina Spittaels

Johannes Joseph Wilhelmus De Haard

Toon Laeremans

Michael John Scott Saunders

Cornelia Dorner-Ciossek

Christophe Blanchetot

Gerald Beste

John Edward Park

Martin Lenter

Stefan Hoerer

Jo Vercammen

Lothar Kussmaul

Sven Jähnichen

Maria Gonzalez

Hendrik Adams

Katharina Zimmerman

David Andre Baptiste Maussang Detaille

Marcel Hoffman

Marcel Hoffmann

David André Baptiste Maussang-Detaille

The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the present invention provides immunoglobulin single variable domains inhibiting CXCR7 mediated tumor growth.

Biological materials related to CXCR7

The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes.

The present invention relates to amino acid sequences that are directed against G-protein coupled receptors (GPCRs), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.

Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders

The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.

A-beta binding polypeptides

A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a GPCR polypeptide, or fragment thereof, and measuring a compound-GPCR property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including second messenger and/or amyloid beta peptide levels. Therapeutic methods, and pharmaceutical compositions including effective amyloid-beta precursor processing-inhibiting amounts of GPCR expression inhibitors, are useful for treating conditions involving cognitive impairment such as Alzheimers Disease.

Methods compositions and compound assays for inhibiting amyloid-beta protein production

A method for identifying compounds that inhibit amyloidal-beta precursor protein processing in cells, comprising contacting a test compound with a GPCR polypeptide, or fragment thereof, and measuring a compound-GPCR property related to the production of amyloidal-beta peptide. Cellular assays of the method measure indicators including second messenger and/or amyloid beta peptide levels. Therapeutic methods,and pharmaceutical compositions including effective amyloidal-beta precursor processing-inhibiting amounts of GPCR expression inhibitors, are useful for treating conditions involving cognitive impairment such as Alzheimers Disease.

Methods for identifying a compound that inhibits the procession of amyloid-beta protein production in a mammalian cell expressing APP and overexpressing a G-protein coupled receptor in the cell

Growing community of inventors

Tielen, Belgium

Pascal Gerard Merchiers